Status:
TERMINATED
Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
Lead Sponsor:
Syntara
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy, safety and tolerability of two dosages of a new drug TPI ASM8 administered by inhalation for 14 days to mild to moderate asthmatic patients, aged between 18-65, ...
Detailed Description
See above
Eligibility Criteria
Inclusion
- Age 18-65 y. old, non or ex-smokers for \> 6 months
- Mild to moderate asthmatic in general good health
- On either low-dose inhaled corticosteroid or steroid naive
- No other asthma medication
- Regular sputum producer
- EOS more than 3% at randomization,
- FEV1 \> 70%
Exclusion
- Respiratory infection within last 4 weeks
- Any condition that may affect the conduct of the study as per the investigators
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00402948
Start Date
February 1 2007
End Date
December 1 2007
Last Update
December 3 2012
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Calgary COPD & Asthma Program
Calgary, Alberta, Canada, T2N 4N1
2
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
3
Gordon and Leslie Diamond Health Care Centre
Vancouver, British Columbia, Canada, V5Z 1M9
4
St-Paul's Hospital
Vancouver, British Columbia, Canada, V6Z iY6